Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2018

Open Access 06.10.2017 | Original Article

HPV vaccination in Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their opinions toward the vaccine

verfasst von: Masaaki Sawada, Yutaka Ueda, Asami Yagi, Akiko Morimoto, Ruriko Nakae, Reisa Kakubari, Hazuki Abe, Tomomi Egawa-Takata, Tadashi Iwamiya, Shinya Matsuzaki, Eiji Kobayashi, Kiyoshi Yoshino, Tadashi Kimura

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

In Japan, the cervical cancer preventative HPV vaccination rate has dramatically declined, directly as a result of repeated broadcasts of so-called adverse events and the resulting suspension of the government’s recommendation. Our previous survey of obstetricians and gynecologists in Japan regarding their opinions toward HPV vaccination revealed that these key specialists were as negatively influenced by the reports of purported negative events as were the general population. Here, we report a 3-year follow-up survey of these clinicians.

Methods

We reused the same questionnaire format as used in our 2014 survey, but added new questions concerning opinions regarding a WHO statement and reports of a Japanese nation-wide epidemiological study related to the adverse events, released in 2015 and 2016, respectively.

Results

The response rate was 46% (259/567): 5 (16.1%) of 31 doctors had inoculated their own teenaged daughters during the time period since the previous survey, despite the continued suspension of the governmental recommendation, whereas in the previous survey none of the doctors had done so. Among the respondents, the majority claimed awareness of the recent pro-vaccine WHO statement (66.5%), and of the report of a Japanese epidemiological study (71.5%), and a majority affirmed they currently held positive opinions of the safety (72.7%) and effectiveness (84.3%) of the HPV vaccine.

Conclusions

Our re-survey of Japan’s obstetricians and gynecologists regarding their opinions about the HPV vaccine found that their opinions have changed, potentially leading to a more positive future re-engagement for HPV vaccination in Japan.
Literatur
2.
Zurück zum Zitat Ueda Y et al (2015) Japan’s failure to vaccinate girls against human papillomavirus. Am J Obstet Gynecol 212:405–406CrossRefPubMed Ueda Y et al (2015) Japan’s failure to vaccinate girls against human papillomavirus. Am J Obstet Gynecol 212:405–406CrossRefPubMed
4.
Zurück zum Zitat Sekine M et al (2016) Japanese crisis of HPV vaccination. Int J Pathol Clin Res IJPCR-2-039 2(2):1–3 Sekine M et al (2016) Japanese crisis of HPV vaccination. Int J Pathol Clin Res IJPCR-2-039 2(2):1–3
5.
Zurück zum Zitat Egawa-Takata et al (2015) Survey of Japanese mothers of daughters eligible for human papillomavirus vaccination on attitudes about media reports of adverse events and the suspension of governmental recommendation for vaccination. J Obstet Gynaecol Res 41:1965–1971CrossRefPubMed Egawa-Takata et al (2015) Survey of Japanese mothers of daughters eligible for human papillomavirus vaccination on attitudes about media reports of adverse events and the suspension of governmental recommendation for vaccination. J Obstet Gynaecol Res 41:1965–1971CrossRefPubMed
6.
Zurück zum Zitat Bratic JS et al (2016) Update on barriers to human papillomavirus vaccination and effective strategies to promote vaccine acceptance. Curr Opin Pediatr 28:407–412CrossRefPubMed Bratic JS et al (2016) Update on barriers to human papillomavirus vaccination and effective strategies to promote vaccine acceptance. Curr Opin Pediatr 28:407–412CrossRefPubMed
7.
Zurück zum Zitat Egawa-Takata et al (2016) Human papillomavirus vaccination of the daughters of obstetricians and gynecologists in Japan. Int J Clin Oncol 21:53–58CrossRefPubMed Egawa-Takata et al (2016) Human papillomavirus vaccination of the daughters of obstetricians and gynecologists in Japan. Int J Clin Oncol 21:53–58CrossRefPubMed
10.
Zurück zum Zitat Tanaka Y et al (2016) Outcomes for girls without HPV vaccination in Japan. Lancet Oncol 17:868–869CrossRefPubMed Tanaka Y et al (2016) Outcomes for girls without HPV vaccination in Japan. Lancet Oncol 17:868–869CrossRefPubMed
Metadaten
Titel
HPV vaccination in Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their opinions toward the vaccine
verfasst von
Masaaki Sawada
Yutaka Ueda
Asami Yagi
Akiko Morimoto
Ruriko Nakae
Reisa Kakubari
Hazuki Abe
Tomomi Egawa-Takata
Tadashi Iwamiya
Shinya Matsuzaki
Eiji Kobayashi
Kiyoshi Yoshino
Tadashi Kimura
Publikationsdatum
06.10.2017
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1188-9

Weitere Artikel der Ausgabe 1/2018

International Journal of Clinical Oncology 1/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.